Information and Education for the Pharmaceutical and Biopharmaceutical Community
Adalbert Strasse 9, Glienicke, Berlin 16548,Other, Germany
The Parenteral Drug Association (PDA) is the leading global provider of science, technology and regulatory information and education for the pharmaceutical and biopharmaceutical community. Founded in 1946 as a non-profit organisation, PDA is committed to developing scientifically sound, practical technical information and resources to advance science and regulation through the expertise of its more than 9,500 members worldwide.
It is PDA’s vision to be the foremost global provider of science, technology and regulatory information and education for the pharmaceutical and biopharmaceutical industry.
It is PDA’s mission to develop scientifically sound, practical technical information and resources to advance science and regulation for the pharmaceutical and biopharmaceutical industry through the expertise of our global membership.
PDA’s mission elements are to:
In addition to sponsoring educational conferences and training courses, PDA publishes the PDA Journal of Pharmaceutical Science and Technology and the PDA Letter, which focus on current industry and regulatory news. In keeping with its 60-year history of promoting the growth of pharmaceutical science and technology, PDA introduced the PDA Training and Research Institute (PDA-TRI), in May 1997.
PDA was founded in 1946 as the Parenteral Drug Association by a small group of pharmaceutical manufacturers who recognised the need for an organisation to disseminate technical information within the industry. Today, coordinated through its headquarters and its Training and Research Institute in Bethesda, Maryland, PDA volunteers worldwide carry out its mission of promoting the exchange of rapidly evolving information on the latest technology and regulations concerning high-quality pharmaceutical production.
PDA is the recognised authoritative voice and leading technical organisation in the field of parenteral science and technology. Through the development of technical reports, bulletins and responses to regulatory initiatives, PDA and its members influence the future course of pharmaceutical products technology.
With more than 10,000 individual members worldwide, PDA draws its strength from the technical expertise of its membership. Conferences, meetings and open forums bring together pharmaceutical manufacturers, suppliers, users, academics and regulatory officials to discuss issues of mutual interest. These exchanges of technical knowledge and expertise assist the advancement of pharmaceutical science and technology in the interest of public health.
PDA is the recognised authoritative voice and leading organisation in the field of pharmaceutical and biopharmaceutical science, technology and regulation. PDA membership puts you on the cutting edge of the profession with direct access to leading decision makers, the latest technical reports, and scientific and regulatory information you won’t find anywhere else.
Seven member benefits:
Maximise your company’s exposure to key decision makers in the pharmaceutical and biopharmaceutical industries as an exhibitor and/or sponsor at a PDA event. Meet potential buyers and take advantage of the opportunity to:
PDA offers exhibitor and sponsorship opportunities at a variety of events, including conferences, forums and educational courses which attract attendees from around the globe. Over the next few years, PDA will host a number of conferences featuring multiple exhibit and sponsorship opportunities, guaranteed to attract hundreds of attendees.
From their beginnings more than 25 years ago, single use systems (SUS) have evolved to become a hot topic within the biopharmaceutical industry. The technology has its roots in filtration technology and blood containers, moving through simple, small-scale culture systems such as roller bottles an
The PDA Europe Workshop on ATMPs 2011 was held in collaboration with Finnish Medicines Agency (Fimea) in Helsinki, Finland, on 7-8 June 2011. The conference was opened by the director general of Fimea, Dr Sinikka Rajaniemi. In her introductory talk, Dr Rajaniemi highlighted the advance
By Joachim Leube, Bayer HealthCare Manufacturing, Italy New options of therapy are needed for a considerable number of diseases. Nowadays research in this field has extended from classical big pharmaceutical industries to a large number of smaller, often just recently founded org
By Volker Eck, PhD, PDA Europe Does this sound familiar to you? "You have not established and documented the accuracy, sensitivity, specificity, and reproducibility of test methods as required by 21 CFR § 211.165(e)." "The test methods performed for XXX USP have no
By Volker Eck, PhD, senior director science and technology, PDA The Parenteral Drug Association (PDA) held the PARENTERALS 2010 conference in Berlin on 26-28 October 2010 with delegates from 20 countries representing over 95 companies and nine regulatory bodies. Highlig
Adalbert Strasse 9, Glienicke
Berlin 16548
Other
Germany